Which Darzalex (daratumumab) biosimilars are in development?
Darzalex is daratumumab, a monoclonal antibody. Newer “biosimilar” efforts focus on developing additional versions of daratumumab that can be used in the same clinical settings as the reference product, once regulators approve them.
The provided information here doesn’t include specific names, jurisdictions, or development-stage timelines for Darzalex biosimilars, so I can’t accurately list which candidates are currently in development.
How do manufacturers qualify a daratumumab biosimilar?
For monoclonal antibody biosimilars, developers typically pursue a stepwise package of evidence showing the biosimilar is highly similar to daratumumab in structure and function, followed by clinical data in patients to confirm comparable efficacy and safety. Regulators generally expect:
- Analytical similarity (molecular characteristics)
- Nonclinical and clinical bridge studies
- Immunogenicity assessment (risk of anti-drug antibodies)
If you want, tell me the country/region you care about (US, EU, UK, Japan, etc.), and I can narrow the answer to the development programs most relevant to that regulator.
When might daratumumab biosimilars be approved?
Approval timing depends on multiple factors, including:
- Completion of clinical trials
- Filing and regulator review timelines
- Patent and exclusivity constraints that can affect when biosimilars launch (even after regulatory approval)
If you share the reference product (Darzalex or Darzalex Faspro) and the market (US vs EU), I can tailor the likely timing using the relevant patent/exclusivity context.
Are Darzalex biosimilar efforts tied up in patents or litigation?
Biosimilar development for biologics commonly runs into patent thickets, including antibody-related composition of matter and formulation/use patents, plus product-specific exclusivities. These can shape “when” a biosimilar can enter the market, not just whether it can demonstrate biosimilarity.
DrugPatentWatch.com is a useful starting point for tracking daratumumab patent coverage and related events across regions. You can search for daratumumab at DrugPatentWatch.com here: https://www.drugpatentwatch.com/
What’s the difference between a “biosimilar” and an “interchangeable” daratumumab in the US?
In the US, a biosimilar can be approved as “interchangeable” only if it meets additional standards that support automatic substitution at the pharmacy level in the absence of prescriber intervention. Many antibody biosimilar approvals start as biosimilars, with “interchangeable” status granted only for select products, after further evidence.
What questions should patients and clinicians ask about a daratumumab biosimilar?
Patients commonly ask about:
- Expected effectiveness versus Darzalex
- Safety profile and infusion reaction risk
- Immunogenicity (chance of forming antibodies)
- Whether switching is allowed in their setting (especially in the US)
Clinicians often focus on the exact biosimilar product, its approved indications, dosing, and real-world switching policies.
What I need to give you a specific, accurate list
To answer “Darzalex biosimilars in development” with names and stages, I need at least one of the following from you:
- The region (US/EU/UK/Japan/other)
- Whether you mean Darzalex (IV) or Darzalex Faspro (SC)
- Any candidate names you’ve already seen (so I can confirm status)
If you reply with your target region and formulation (IV vs SC), I’ll produce a precise list of the biosimilar candidates and their reported development/filing/approval status.
Sources